<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">20402634</PMID>
      <DateCompleted>
        <Year>2010</Year>
        <Month>09</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-5607</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2010</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Mini reviews in medicinal chemistry</Title>
          <ISOAbbreviation>Mini Rev Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Saxagliptin: a new drug for the treatment of type 2 diabetes.</ArticleTitle>
        <Pagination>
          <StartPage>759</StartPage>
          <EndPage>765</EndPage>
          <MedlinePgn>759-65</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Saxagliptin (BMS-477118) has been recently FDA approved drug for the management of T2DM developed by Bristol-Myers Squibb and AstraZeneca under the trade name Onglyza. Saxagliptin is a nitrile-containing selective, potent, reversible and durable DPP IV inhibitor developed as an alternative second-line adds on to Metformin in place of a sulphonylurea. Saxagliptin increases and prolongs the action of incretin hormones by inhibiting the DPP IV enzyme that inactivates incretins usually within minutes. Saxagliptin is well absorbed and has low plasma protein binding and displays slow-binding properties to DPP IV. Saxagliptin is metabolized in vivo to form an active metabolite (BMS-510849), which is twofold less potent than the parent molecule. The X-ray crystallography revealed that Saxagliptin is covalently bound to the DPP IV active site. In drug-native patients with T2DM and inadequate glycemic control, once-daily Saxagliptin monotherapy for 24 wks demonstrated clinically meaningful with no weight gain and generally well tolerated.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thareja</LastName>
            <ForeName>Suresh</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh-160014, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aggarwal</LastName>
            <ForeName>Saurabh</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Malla</LastName>
            <ForeName>Priyanka</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haksar</LastName>
            <ForeName>Diksha</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bhardwaj</LastName>
            <ForeName>Tilak Raj</ForeName>
            <Initials>TR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kumar</LastName>
            <ForeName>Manoj</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Mini Rev Med Chem</MedlineTA>
        <NlmUniqueID>101094212</NlmUniqueID>
        <ISSNLinking>1389-5575</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054795">Incretins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9GB927LAJW</RegistryNumber>
          <NameOfSubstance UI="C502994">saxagliptin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.14.5</RegistryNumber>
          <NameOfSubstance UI="D018819">Dipeptidyl Peptidase 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PJY633525U</RegistryNumber>
          <NameOfSubstance UI="D000218">Adamantane</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018819" MajorTopicYN="N">Dipeptidyl Peptidase 4</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054795" MajorTopicYN="N">Incretins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>44</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2010</Year>
          <Month>4</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2010</Year>
          <Month>4</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2010</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2010</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2010</Year>
          <Month>9</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">20402634</ArticleId>
        <ArticleId IdType="doi">10.2174/138955710791572424</ArticleId>
        <ArticleId IdType="pii">MRMC Epub-128</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
